IDYA IDEAYA Biosciences
- 29.970
- +0.720+2.46%
- 29.970
- 0.0000.00%
IDEAYA Biosciences News
Buy Rating on IDEAYA Biosciences Amidst Promising Uveal Melanoma Drug Developments and Strategic Pipeline Expansion
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
IDEAYA Biosciences Is Maintained at Outperform by Wedbush
Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $52
A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $35 to $66
IDEAYA Biosciences Analyst Ratings
IDEAYA Biosciences (IDYA) Receives a Buy From RBC Capital
Buy Rating Affirmed for IDEAYA Biosciences on Promising Clinical Data and Regulatory Clarity for Darovasertib in Uveal Melanoma
Stifel Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $68
IDEAYA Biosciences Is Maintained at Buy by Stifel
IDEAYA Biosciences Analyst Ratings
LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $65
Citi Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $58
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
Buy Rating Affirmed for IDEAYA Biosciences Amid Promising Developments and Pipeline Expansion
Buy Rating Affirmed for IDEAYA Biosciences Amidst Strategic Advancements and Robust Pipeline Development
IDEAYA Biosciences Analyst Ratings
IDEAYA Biosciences Price Target Maintained With a $54.00/Share by Wedbush
Analysts Offer Insights on Healthcare Companies: Rigel (RIGL) and IDEAYA Biosciences (IDYA)
Analysis
Price Target
No Data
No Data